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Abstract
Purpose Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cogni-
tive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized 
selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.
Methods Starting one day before surgery, patients underwent neuropsychological assessment every three months during 
standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reli-
able Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent 
follow up, a decline of RCI ≤ − 1 on at least two of the three tests in the selection was considered cognitive decline. We 
performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) 
and covariate age to predict progressive disease.
Results Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred 
by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was 
absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case 
of cognitive decline was 5.05 (p < 0.01) compared to stable performance.
Conclusions Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease 
progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may 
be a noninvasive addition to disease monitoring without overburdening patients and clinical care.
Keywords Cognitive functioning · High-grade glioma · RANO · Disease progression · Neuropsychological assessment
Introduction
Identification of reliable prognostic indicators for disease 
progression and overall survival is a principal aim in care 
for patients with high-grade gliomas (HGG), for treatment 
planning and to inform patients. Age and performance status 
(PS) are generally considered the major prognostic factors 
from a clinical perspective [1–3].These characteristics, how-
ever, may be interrelated with or confounded by other fac-
tors, such as therapeutic strategy or varying disease symp-
toms [1, 4], that are not always accounted for.
Interest in the prognostic value of cognitive functioning 
in the clinical management of glioma patients is growing [1, 
5–9]. Cognitive functioning depends on neuronal synchrony 
across brain regions [10]. Invasive growth, reactive changes 
in peritumoral tissue and increased intracranial pressure may 
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all disrupt network functioning needed for cognitive perfor-
mance [11].
Cognitive status before surgery or oncological treatment 
has been reported as a predictor of (progression-free) sur-
vival time [7] independent of age and Karnofsky PS (KPS) 
[9] and within RPA-RTOG classes [12]. Furthermore, Mey-
ers [8] reported that performance decline over time on one 
of nine cognitive tests preceded radiological evidence of 
progressive disease (PD) in HGG in 85% of cases and by 
a median of 4 to 7 weeks. In a heterogeneous sample of 
patients with brain tumors, Armstrong and colleagues [5] 
showed that a decline of one standard deviation (SD) on the 
standardized mean of three to five tests per patient selected 
based on tumor location, was accompanied by a fivefold 
increase in chance of PD.
Cognitive deterioration over time might thus provide 
information about tumor activity during the course of the 
disease [5, 8, 13, 14]. A targeted test selection, e.g., tumor 
location-based as done by Armstrong [5] may increase effi-
ciency of assessment. However, dysfunction of specific cog-
nitive domains may not be reliably determined by location 
alone [15, 16] as tumors affect cerebral functioning outside 
their location [17].
In this study, we argue that disease-related cognitive 
dysfunction in HGGs, and individual differences therein, 
may also be detected by considering the manner in which a 
patient’s performance changes early after tumor resection. 
We hypothesize that the functions that show the largest 
recovery shortly after surgery are the ones that suffered the 
largest burden from tumor-related edema and mass effect, 
and that these same functions may deteriorate first amid 
recurrent disease activity. In a sample of newly diagnosed 
HGG, we constructed a personalized test selection for each 
patient, based on a subset of three neuropsychological tests 
that demonstrated most improvement within three months 
after resection. We subsequently investigated whether dete-
rioration on this selection coincided with, and predicted PD.
Materials and methods
Patients
Patients undergoing resection at the Elisabeth-TweeSt-
eden Hospital (ETH), Tilburg, the Netherlands, between 
August 2015 and September 2017 for histopathologically 
confirmed grade III AA or GBM were included. Patients 
received clinical follow up either at ETH or Catharina Hos-
pital (CH) in Eindhoven, the Netherlands. Exclusion criteria 
were age < 18, presence of progressive neurological disease, 
psychiatric or acute neurological disorder within the past 
2 years, previous intracranial surgery, reduced testability 
(e.g. lack of proficiency in Dutch, estimated IQ < 85). All 
participants provided written informed consent.
Study procedure and design
At the neurosurgery department of ETH, patients with brain 
tumors undergo neuropsychological assessment (NPA) as 
part of clinical care 1 day before (T0) and 3 months after 
(T3) neurosurgical treatment. Around T3, patients were 
asked to participate in this prospective longitudinal study 
by a neuro-oncology nurse practitioner, and underwent three 
monthly NPA and MRI, for up to 24 months after surgery 
(T24; 9 NPA’s in total) or until confirmed progressive dis-
ease (PD) at their clinical follow-up site. NPA and MRI were 
performed on the same day, but NPA was always done before 
the patient was informed of the results of the MRI. Approval 
for the study was given by Medical Ethics Committee Bra-
bant (File No. NL41351.008.12).
Measures
Sociodemographic and clinical measures
Sociodemographic information was gathered through semi-
structured interview at T0. Clinical information (tumor char-
acteristics, extent of resection, KPS, medication, adjuvant 
treatment) was retrieved from electronic charts. Pre-surgical 
tumor volumes were determined through semi-automatic 
segmentation using BrainLab Elements [18] software on 
T1-post contrast enhanced series.
Neuropsychological assessment
The Dutch translation of the CNS Vital Signs (CNS VS) 
computerized test battery consists of seven tasks based on 
conventional paper-and-pencil tests [19]. Completion using 
the local software application on a notebook computer took 
30–40 min. Two additional paper-and-pencil tasks were 
administered: Digit Span task [20], and a Letter Fluency 
task [21]. An overview of task content and score computa-
tion is provided in the supplementary Table. Trained test 
administrators conducted assessments.
MRI‑cerebrum and time until PD
Evaluations of the three monthly MRI scans were conducted 
by a trained neurologist (MB) under supervision of a sen-
ior neurologist (CT), both unaware of patients’ cognitive 
status. The baseline for comparison follow up MRI scans 
(at T3, T6, etc.) was the first post-operative scan ( ≤ 48 h 
after surgery). We adopted the response assessment crite-
ria for HGG by the RANO Working Group [22] for disease 
status evaluation: (1) ≥ 25% increase of the product of the 
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maximum diameters of contrast-enhancing lesions (2) sig-
nificant increase of lesions in T2-weighted/ FLAIR series (3) 
presence of new contrast-enhancing lesions outside radiation 
field (4) significant clinical deterioration not attributable to 
medication or comorbid conditions, or (5) clear progression 
of a non-measurable lesion.
Cognitive change as a personalized predictor
Reliable change
Regression-based Reliable Change Indices (RCI), aimed at 
determining whether change between assessments in indi-
vidual patients reflected relevant change, controlling for 
confounding factors related to repeated testing (e.g. flawed 
test–retest reliability, practice effects) [23, 24], were com-
puted for each of the 10 test scores. A positive RCI value 
indicates improvement, a negative RCI value indicates 
decline. RCI’s were based on repeated testing data of healthy 
Dutch individuals from Rijnen [24] (CNS VS), Schmand 
[21] (Letter Fluency), and an ongoing study in the ETH 
(Digit Span test); CAR study A, ClinicalTrials.gov refer-
ence nr. NCT02953756.
Personalized selection and criterion for cognitive decline 
(CD)
For each patient, the three tests with the highest RCIs 
between T0 and T3 were selected. We opted to select three 
tests in accordance with previous similar studies [5, 8], and 
with the goal of a small selection of tests for potential future 
clinical purposes. All follow-up RCI’s were calculated using 
T3 NPA as baseline (T6–T3, T9–T3, etc.). CD was defined 
as RCI ≤ − 1.00, reflecting a standardized difference score of 
− 1, on at least two of the three selected tests at any follow 
up interval.
Statistical analyses
Using the Survival package in Rstudio, a discrete Cox pro-
portional hazards model with two covariates was performed 
(α = 0.05): a dichotomous time-dependent covariate (CD vs. 
stable performance) and age at time of surgery. Cases who 
dropped out before PD, completed follow up (T24) progres-
sion-free, or showed stable disease at the end of the study 
(August 2018), were censored. Median time to PD and to 
CD were computed. Z-scores, corrected for age, sex and 
educational level based on a healthy control sample [25] 
were computed to investigate whether patients had cogni-
tive impairment before surgery (Z ≤ − 1.5). Group-level 
characteristics of patients with PD, without PD, with CD, 
and without CD were computed (no statistical comparisons 
due to sample sizes).
Results
Patients
Thirty-five of 70 (50%) patients eligible for participation 
were included in the study. Unwillingness, anticipated inten-
sity of repeated NPA, and follow-up care in a non-partici-
pating center were reasons for declining participation. Ten 
out of 35 patients were excluded from analyses, because 
of invalid or incomplete T0 NPA (n = 6), or absent T6 data 
(consent withdrawal; n = 3, referral to non-participating 
treatment center; n = 1). Analyses showed no differences in 
age, tumor volume, extent of resection or pre-operative KPS 
between excluded patients and the final sample.
The final sample comprised four anaplastic astrocytoma 
(AA) and 21 glioblastoma (GBM). Mean age at time of 
surgery was 53 ± 14 years. See Table 1 for an overview 
of sample characteristics and Table 2 for the personal-
ized test selection per patient. All patients started adjuvant 
Table 1  Sample characteristics
a Classified according to Verhage education coding system [31]
Characteristic N = 25
Male n (%) 17 (68%)
Age at time of surgery (M ± SD, range) 53 ± 14, 19–76
Educational  levela
 Low n (%) 3 (12%)
 Middle n (%) 12 (48%)
 High n (%) 10 (40%)
Diagnosis
 Glioblastoma 21 (84%)
 Anaplastic astrocytoma 4 (16%)
Tumor volume  (cm3), median (range) 37 (4.4–162)
KPS before surgery, mode (range) 90, 80–100
Tumor lateralization n (%)
 Right 15 (60%)
 Left 10 (40%)








Corticosteroids before surgery 17 (68%)
Anti-epileptics before surgery 8 (32%)
Macroscopic extent of resection
 Gross total resection ( > 90%) 17 (68%)
 Gross subtotal resection ( < 90%) 8 (31%)
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chemoradiation according to protocol [26]. Twenty-one 
patients completed treatment as planned during study par-
ticipation. Temozolomide monotherapy was discontinued 
in four patients, either on patient’s request (n = 1, around 
T6), because of PD during (n = 2, around T6) or due to 
treatment-related toxicity (n = 1, between T6 and T9). 
In 23 out of 25 patients, all three selected tests with 
the highest RCI from T0 to T3 were positive scores ( > 0), 
indicating improvement after surgery. In two patients, the 
selection also contained tests with negative values (high-
est RCI’s were 0.62, 0.23, and − 0.25 in one patient, 1.76, 
− 0.18, and − 0.20 in another patient).
Fifteen out of 25 patients (60% of the sample) showed 
PD according to RANO during follow up (see Table 3 for 
evaluations of PD). Eleven out of 25 showed CD during 
follow up. Within the “PD group”, the median time-point 
to PD was T9, while within the “CD group”, the median 
time-point to CD was T6.
CD preceded (n = 4) or was present at time of (n = 5) PD 
in nine out of 15 patients with PD. See Fig. 1 for a visualiza-
tion of individual follow-up periods and the timing of CD 
relative to PD. Five of the six patients who showed stable 
cognitive performance according to our criterion, despite 
PD, showed RCI ≤ − 1 on one of their selected tests at time 
of PD, while showing no RCI ≤ − 1 on their unselected tests.
In 10 of 25 patients (40%), PD did not occur during study 
participation. Eight out ten (80%) were stable performers 
throughout follow up (median follow up time-point T12, 
range T6–T24). Two patients showing CD despite stable 
disease, did so at T6 and T9 respectively.
Table 3 shows descriptive characteristics of the four 
groups (no statistical comparisons). The group demon-
strating both CD and PD was the only group in which KPS 
below 90 was observed at time of final NPA. AED use was 
high among these patients compared to the other groups, 
but the majority (four out of six) used medication because 
Table 2  Cognitive parameters 
and tumor location per patient
a Active participation at end of study
b Dropout before PD
c Completion of T24 without PD
Diagnosis Age Location Hemisphere Selected tests Impairment on 




GBM 18–20 Frontal Left SAT, LF, SDC 3/3 Noc
GBM 60–70 Parieto–occipital Right SAT, VEM, SDC 2/3 Yes
AA 30–40 Frontal Left DSFW, LF, SAT 1/3 Noc
GBM 60–70 Occipital Left VIM, DSB, DSF 0/3 Yes
GBM 50–60 Occipital Right SDC, CPT, FTT 2/3 Yes
GBM 50–60 Fronto–parietal Right SAT, VIM, VEM 1/3 Yes
GBM 40–50 Frontal Right SAT, CPT, FTT 2/3 Yes
GBM 60–70 Parietal Right CPT, SAT, VEM 3/3 Yes
GBM 60–70 Occipital Right VIM, SAT, VEM 3/3 Yes
GBM 40–50 Frontal Left FTT, CPT, SAT 0/3 Yes
GBM 50–60 Parieto–occipital Left SAT, CPT, SDC 1/3 Nob
GBM 50–60 Parietal Left SAT, VIM, FTT 3/3 Yes
GBM 50–60 Parieto–occipital Right FTT, CPT, SDC 3/3 Nob
AA 30–40 Frontal Right VIM, VEM, LF 0/3 Noc
GBM 60–70 Temporo–parietal Left FTT, SAT, Stroop 0/3 Yes
GBM 70–80 Parietal Right FTT, SAT, Stroop 2/3 Yes
GBM 50–60 Frontal Right FTT, VIM, DSF 0/3 Yes
GBM 50–60 Occipital Right VEM, VIM, LF 2/3 Yes
GBM 50–60 Temporo–parietal Left FTT, VEM, Stroop 0/3 Yes
GBM 30–40 Occipital Right FTT, DSF, SDC 2/3 Nob
GBM 70–80 Temporal Right Stroop, SAT, VIM 0/3 Yes
GBM 50–60 Occipital Right VIM, Stroop, FTT 1/3 Noa
GBM 50–60 Mesiotemporal Left FTT, LF, SDC 3/3 Noa
AA 50–60 Temporal Right SAT, SDC, DSB 3/3 Noa
AA 20–30 Parieto–occipital Left FTT, VEM, DSB 2/3 Noa
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of a pre-surgical insult. The other two started AED therapy 
due to a seizure during follow up (both in the interval prior 
to PD). The group with stable disease and stable cognitive 
performance appeared relatively young and to comprise 
fewer males compared to the other groups.
The Cox proportional hazards model showed a hazard 
ratio (HR) for PD of 5.05; 95% CI 1.50–17.02, p < 0.01 
(model χ2[1] = 13.6, p < 0.01, c-index = 0.80), suggest-
ing a 405% increase in chance of RANO-confirmed PD if 
patients met the criterion of CD compared to stable cogni-
tive performance, independent of age. Age itself was not a 
significant predictor (HR = 1.04, p > 0.1) of PD.
Discussion
This study investigated whether post-surgical cognitive 
decline (CD) on a personalized selection of three neu-
ropsychological tests concurred with and predicted pro-
gressive disease (PD) according to RANO [22] in 25 
patients with GBM or AA.
Decline in cognitive performance—deterioration of at 
least one RCI point on at least two of the three selected 
tests—concurred with, or manifested one or two interval(s) 
before, RANO-confirmed PD in nine out of 15 (60%) of 
Table 3  Descriptive characteristics and RANO [22] evaluations grouped by disease status and cognitive status on personalized test selections
Percentages are calculated within each group
a Only case of non-local tumor recurrence
Progressive disease (n = 15) Decline on tests (n = 9) Stable on tests (n = 6)
Age before surgery 60.0 ± 7.6 58.3 ± 10.7
Low education 0 (0%) 1 (16.7%)
High education 4 (44.4%) 3 (50%)
Male 7 (77.8%) 5 (83.3%)
Impairment on ≥ 1 selected test at T0 5 (55.6%) 5 (83.3%)
Tumor in left hemisphere 4 (44.4%) 1 (16,7%)
Macroscopic total resection 6 (66.7%) 3 (50%)
Time to CD (median) T6 n/a
Time to PD (median) T6 T12
KPS < 90 at time of PD 5 (55.6%) 0 (0%)
AEDs at time of PD (%, n at T3) 6 (66.7%, 4) 1 (16.7%, 1)
Corticosteroids at time of PD 2 (22.2%) 0 (0%)
RANO evaluation
 New contrast-enhancing lesion outside radiation  fielda 0 (0%) 1 (16.7%)
 Increase ≥ 25% in the sum of the products of perpendicular diameters 5 (55.6%) 3 (50%)
 Clinical deterioration not attributable to medication or comorbidity ( ≥ 12 weeks 
post-chemoradiation)
1 (11.1%) 0 (0%)
 Significant increase in T2/FLAIR non-enhancing lesion 0 (0%) 0 (0%)
 Clear progression of a nonmeasurable lesion 3 (33.3%) 2 (33.3%)
Stable disease (n = 10) Decline on tests (n = 2) Stable on tests (n = 8)
Age before surgery 55.5 ± 3.54 40.3 ± 15.6
Low education 0 (0%) 2 (25%)
High education 1 (50%) 4 (50%)
Male 2 (100%) 3 (37.5%)
Impairment on ≥ 1 selected test at T0 2 (100%) 7 (87.5%)
Tumor in left hemisphere 1 (50%) 4 (50%)
Macroscopic total resection 2 (100%) 6 (75%)
Time to CD (Median) T6 n/a
Time to PD (Median) n/a n/a
KPS < 90 at time of censoring 0 (0%) 0 (0%)
AEDs at time of censoring (%, n at T3) 0 (0%, 0) 2 (25%, 2)
Corticosteroids at time of censoring 0 (0%) 0 (0%)
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recurrences. Of the six patients with PD who did not meet 
our criterion for CD, five showed RCI ≤ − 1on one of their 
selected tests, but no such decline on their unselected 
tests. Further consistent with our hypothesis and previous 
reporting [27], eight out of 10 patients with stable disease 
remained cognitively stable throughout participation. The 
predictive model showed a 405% increase in chance for PD 
(HR = 5.05) in case of CD, independent of age.
Our findings support existing reports of (change in) cog-
nitive functioning as a clinical marker of disease activity 
in patients with brain tumors [5, 8, 13, 28]. Gradual, wide-
spread impairment of network functioning over time may 
underlie the sensitivity of cognitive performance to disease 
progression. Using a uniform test selection in patients with 
recurrent HGG, Meyers and colleagues [8] reported a higher 
proportion of patients showing CD (48/56 patients, CD was 
defined as RCI ≤ − 1.645 on one of nine tests) before, or 
at time of, PD compared to our study. It could be that CD 
emerges sooner in patients with progression of already 
recurred HGG. Still, the described criterion for decline was 
based on a more stringent cutoff, but for only one test, and 
time between CD and actual PD seemed to vary considerably 
among patients. Their reported prediction model (requiring 
decline on one of three uniform tests) yielded a HR for PD 
of 2.0 in case of CD.
The hazard ratio of CD (one standard deviation in mean 
performance) on a tumor location-based selection of three to 
five tests found by Armstrong [5] in a sample of 34 patients 
with glial and non-glial tumors, of which 11 demonstrated 
recurrence, was comparable to the one we found. As stated, 
reliable inferences about cognitive (dys-)function may not 
be based on tumor location alone [15]. In our sample of 
mainly GBMs, we did not observe a one-to-one relation-
ship between tumor location and the personalized selection 
of tests, e.g., Letter Fluency and Shifting Attention tests 
were selected in patients with occipital tumors. The relative 
value of selection approaches (uniform, location-specific, 
personalized) within the context of prediction of PD may be 
compared in one larger sample in the future.
The absence of a gold standard concerning the cut off 
for CD, irrespective of the selection approach, in settings 
where cognition is used as a predictive instead of an out-
come measure also warrants further investigation. The used 
RCI is a suitable measure for change as it conveys a cautious 
estimation of decline. Selecting three tests per patient is in 
accordance with previous approaches [5, 8] and preserves 
briefness required for repeated NPA in the HGG popula-
tion. We must note that the widely adopted RANO criteria 
for HGG are based on current evidence [22] and will likely 
evolve in the future.
Cognitive performance can fluctuate over time due to 
factors (un-)related to disease activity, such as temporary 
corticosteroid use [29] or depressive symptoms [30]. It 
has however been suggested that the main cause of cogni-
tive decline over time is the tumor itself [13]. Cognitive 
stability in eight out of 10 progression-free patients in 
this study also suggests that such factors did not disturb 
cognitive performance strongly (RCI’s remained > − 1) or 
in a personalized pattern. The group with both CD and 
PD did seem to comprise a relatively large proportion of 
Fig. 1  Follow-up duration per patient and time of CD (filled circle) 
and PD. Lines stop at time of RANO PD (bold line) or end of par-
ticipation (dotted line; censoring). Timing of CD differed between 
patients (one patient two intervals before PD, two patients one inter-
val before PD, five patients at time of PD)
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patients using AED’s, although in the majority of cases 
due to a pre-surgical insult. It was also the only group that 
comprised patients with KPS < 90 at time of final NPA/
PD. Clinical status may have interplayed with cognitive 
functioning around the time of PD. We were unable to 
adopt post-surgical decline in KPS or a combined cog-
nition-KPS classification in the statistical model due to 
sample size, but analysis of hazard rates associated with 
CD irrespective of (K)PS decline could be a next step in 
future research.
Sample characteristics should be taken into account in 
interpreting our results. We note that our sample primar-
ily comprised patients with GBM, and the majority of AA 
patients did not show PD. Moreover, 50% of patients who 
were invited to participate in this study declined partici-
pation, e.g., due to anticipated intensity of repeated NPA. 
Patients in good clinical condition at time of inclusion 
might be overrepresented. Furthermore, only 12% of the 
included patients had low educational level. Different cog-
nitive courses might exist between groups who differ on 
these variables.
Results from the personalized prediction model warrant 
further investigation to establish relevance in clinical prac-
tice. Personalized NPA may serve as a noninvasive method 
to complement decision making processes, such as timing 
of second-line therapy in case of unclear or seemingly 
limited tumor growth. Conducting targeted NPA between 
MRI scans may also allow for early detection of recur-
rent disease activity, e.g., in patients whose radiological 
evaluation is conducted over longer intervals due to other 
relatively favorable prognostic features.
Conclusion
In conclusion, our prediction model based on a personal-
ized selection of three neuropsychological tests showed 
CD before or at time of PD in the majority of patients 
with HGG. Eighty percent of progression-free survivors 
showed stable cognitive performance. Patients demonstrat-
ing CD showed five times higher chance of PD compared 
to stable performers. Personalized, longitudinal NPA may 
provide a targeted and sensitive addition to monitoring of 
both cognitive and disease status without overburdening 
patients or care trajectories.
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